problems with tirzepatide Efficacy and Safety of in Adults Obesity or Overweight Published July 21, 2022 N Engl J Med 2022;387:205–216 🔹 Background Obesity and overweight remain major global health associated with FDA Approves Lilly's Zepbound™ (tirzepatide)

In TRIUMPH-4, 18.2% of participants on retatrutide 12 mg discontinued due to adverse events, compared to 12.2% on the 9 mg dose and just 4.0% on placebo

This integrated approach supports sustainable health outcomes and may improve long-term effectiveness if employees discontinue medication

10.3390/molecules23071663 69 ParkE.LimE.YeoS.YongY.YangJ.JeongS.-Y

A blinded extension among participants with baseline BMI 35 continued through 104 weeks, where mean weight loss reached 30.3%

Semaglutide and Breastfeeding If youre a new mom wondering about semaglutide and breastfeeding, youre not alone

[1] [3] The combination may lead to more frequent or severe diarrhea with associated dehydration risk